Prosight Management, LP

Position in ADCT — ADC Therapeutics SA

CIK 1617201 DALLAS, TX

Position in ADCT

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$31,125,000

+$1,199,997 QoQ

Shares Held

8,300,000

-2.1% QoQ

Ownership

6.53%

of shares outstanding

% of Portfolio

5.10%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2022

15 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Prosight Management, LP holds $54,591,706 across 3 Drug Manufacturers - Specialty & Generic names. ADCT ranks #1 (57.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ADCT	ADC Therapeutics SA This page	8,300,000	$31,125,000
2	ALKS	Alkermes plc.	513,632	$18,162,027
3	EBS	Emergent BioSolutions Inc.	639,118	$5,304,679

17 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$31,125,000	8,300,000	-2.1%	Shares	Sole	2026-05-15
2025-12-31	$29,925,003	8,477,338	0.0%	Shares	Sole	2026-02-13
2025-12-31	$29,925,003	8,477,338	+13.5%	Shares	Sole	2026-02-13
2025-09-30	$29,889,212	7,472,303	+3.8%	Shares	Sole	2025-11-14
2025-09-30	$28,781,496	7,195,374	-31.3%	Shares	Sole	2025-11-13
2025-06-30	$28,053,626	10,467,771	+9.7%	Shares	Sole	2025-08-14
2025-03-31	$13,455,635	9,543,004	+0.3%	Shares	Sole	2025-05-15
2024-12-31	$18,934,850	9,515,000	-1.3%	Shares	Sole	2025-02-14
2024-09-30	$30,354,146	9,636,237	+0.7%	Shares	Sole	2024-11-14
2024-06-30	$30,241,200	9,570,000	+35.7%	Shares	Sole	2024-08-14
2024-03-31	$31,655,847	7,050,300	+8.9%	Shares	Sole	2024-05-15
2023-12-31	$10,743,188	6,471,800	+19.8%	Shares	Sole	2024-02-14
2023-09-30	$4,845,630	5,402,041	-3.3%	Shares	Sole	2023-11-14
2023-06-30	$12,005,385	5,583,900	+71.4%	Shares	Sole	2023-08-14
2023-03-31	$6,351,852	3,257,360	+603.1%	Shares	Sole	2023-05-12
2022-12-31	$1,779,110	463,310	+87.1%	Shares	Sole	2023-02-14
2022-09-30	$1,193,576	247,630	—	Shares	Sole	2022-11-14
No filing history on record for this holder in this stock.